Fig. 15

Dasatinib regulates LPS-evoked plasma proinflammatory cytokine levels in wild-type mice. a–c Wild-type mice were injected with dasatinib (20 mg/kg, i.p.) or vehicle (4% DMSO + 30% PEG + 5% Tween 80, i.p.) daily for 4 days, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after LPS or PBS injection, plasma IL-6, IL-1β, and TNF-α levels were measured by ELISA (con, n = 8 mice; LPS, n = 8 mice; dasatinib+LPS, n = 8 mice). d–f Wild-type mice were orally administered dasatinib (20 mg/kg, p.o.) or vehicle (4% DMSO + 30% PEG + 5% Tween 80, p.o.) daily for 4 days, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after LPS or PBS injection, plasma IL-6, IL-1β, and TNF-α levels were measured by ELISA (con, n = 8 mice; LPS, n = 8 mice; dasatinib+LPS, n = 8 mice). g–i Wild-type mice were orally administered dasatinib (20 mg/kg, p.o.) or vehicle (4% DMSO + 30% PEG + 5% Tween 80, p.o.) daily for 2 weeks, followed by injection with LPS (10 mg/kg, i.p.) or PBS. Three hours after LPS or PBS injection, plasma IL-6, IL-1β, and TNF-α levels were measured by ELISA (con, n = 8 mice; LPS, n = 8 mice; dasatinib+LPS, n = 8 mice). One-way ANOVA with Tukey’s post hoc test was used to analyze significant differences. **p < 0.01, ***p < 0.001